Menu
Search
|

Menu

Close
X

Biofrontera AG BFRA.OQ (NASDAQ Stock Exchange Capital Market)

13.00 USD
+0.00 (+0.00%)
As of Jul 18
chart
Previous Close 13.00
Open 13.44
Volume 3
3m Avg Volume 1,024
Today’s High 13.44
Today’s Low 13.44
52 Week High 17.87
52 Week Low 11.25
Shares Outstanding (mil) 38.42
Market Capitalization (mil) 139.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, EUR)
FY18
5
FY17
12
FY16
6
FY15
4
EPS (EUR)
FY18
-0.077
FY17
-0.416
FY16
-0.350
FY15
-0.492
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
14.81
5.73
Price to Book (MRQ)
vs sector
13.44
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
61.28
16.84
LT Debt to Equity (MRQ)
vs sector
25.55
12.51
Return on Investment (TTM)
vs sector
-184.45
14.61
Return on Equity (TTM)
vs sector
-276.38
16.34

EXECUTIVE LEADERSHIP

Ulrich Granzer
Chairman of the Supervisory Board, Since 2016
Salary: €2,000.00
Bonus: --
Hermann Luebbert
Chairman of the Management Board, Chief Executive Officer, Since 2005
Salary: --
Bonus: --
Juergen Baumann
Vice Chairman of the Supervisory Board, Since 2016
Salary: --
Bonus: --
Thomas Schaffer
Chief Financial Officer, Member of the Management Board, Since 2013
Salary: --
Bonus: --
Christoph Duenwald
Member of the Management Board, Chief Commercial Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Hemmelrather Weg 201
LEVERKUSEN     51377

Phone:

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

SPONSORED STORIES